

# 3<sup>rd</sup> Theranostics World Congress on Ga-68 and Radiopeptide Therapy

MARCH 12-14, 2015

**Johns Hopkins Medical Institute**

Thomas B. Turner Auditorium

Baltimore, Maryland – USA

## PROGRAM

CONGRESS CHAIRPERSONS: **Richard L. Wahl (USA), Richard P. Baum (GER) and Martin Pomper (USA)**

Videos are available at <https://vimeo.com/channels/3wtc> Video number indicated in the title (day.videonumber)  
Videos made possible by a grant from [NorCal CarciNET Community](#).

### THURSDAY, MARCH 12

07:00 – 18:00	Registration and Continental Breakfast - Johns Hopkins Thomas B. Turner Auditorium	
<b>08:00 – 08:30</b>	<b>Opening Ceremony (1.1)</b>	
08:00	Opening Remarks	Richard Wahl (USA)
08:10	Pre-Clinical Spotlight	Hans-J. Wester (GER)
08:20	Clinical Spotlight	Richard Baum (GER)
<b>08:30 – 09:30</b>	<b>Scientific Session 1 – <sup>68</sup>Ge/<sup>68</sup>Ga-Generators, Post-Processing and Synthesis Modules</b>	
<i>Chairpersons: Frank Roesch (GER) and Michael Schultz (USA)</i>		
08:30	Generators and Tracer Production (1.2)	Irina Velikyan (SWE)
09:00	Development of a <sup>68</sup> Ga-Ranatensin Analog for Bombesin Receptors in PET Molecular Imaging (1.3)	David Dick (USA) for Clement Morgat (FRA)
09:15	Ethanol Post-Processing of <sup>68</sup> Ga Eluates for Preparation of <sup>68</sup> Ga-Radiopharmaceuticals (1.4)	Elisabeth Eppard (GER)
<b>09:30 – 10:00</b>	<b>COFFEE AND TRADE EXHIBITS</b>	
<b>10:00 – 11:30</b>	<b>Scientific Session 2 – Chemistry: Chelators and Labeling Chemistry for Theranostic Isotopes</b>	
<i>Chairperson: Henry VanBrocklin (USA) and Hans-J. Wester (GER)</i>		
10:00	State of the Art – Chelators (1.5)	Johannes Notni (GER)
10:30	One-Step, Mild Efficient <sup>68</sup> Ga “Cold” PET Kits: Performance Characteristics and Robustness of tris(hydroxypyridinone) Chelators (1.6)	Jennifer Young (UK)

10:45	New Bifunctional tris(hydroxypyridinone) Chelators for Rapid Labelling with <sup>68</sup> Ga: Conjugates with SSTR2- and αvβ3-Targeting Peptides (1.7)	Michelle Ma (UK)
<b>Thursday, March 12 - continued</b>		
11:00	Rapid <sup>68</sup> Ga-Radiolabelling of Proteins in Mild Conditions Exploiting a Novel tris(hydroxypyridinone) Bifunctional Chelator (1.8)	Cinzia Imberti (UK)
11:15	Shortcut to High-Affinity <sup>68</sup> Ga and <sup>64</sup> Cu Radiopharmaceuticals: One-pot Click Chemistry Trimerisation on the TRAP Platform (1.9)	Johannes Notni (GER)
<b>11:30 – 12:45</b>	<b>LUNCH AND TRADE EXHIBITS - GALLIUM USERS GROUP MEETING</b>	
<b>12:45 – 13:15</b>	<b>PLENARY ADDRESS ~ Jean-Claude Reubi (GER): Peptide Membrane Receptors as Targets in Cancer (1.0)</b>	
<b>13:15 – 14:30</b>	<b>Scientific Session 3 – Theranostic Targeting Vectors (I)</b>	
<i>Chairpersons: Dong Soo Lee (KOR) and Konstantin Zhernosekov (GER)</i>		
13:15	Radiopeptides Targeting GPCR Agonists and Antagonists (1.10)	Renata Mikolajczak (GER)
13:45	Requirements on Specific Activity (SA) of <sup>177</sup> Lu to Radiolabel DOTATATE for PRRT (1.11)	Woeter AP Breeman (NED)
14:00	<sup>68</sup> Ga-Aquibepirin and <sup>68</sup> Ga-Avebetrin for Complementary, Selective PET-Imaging of Integrin Subtypes α5β1 and αvβ3 (1.12)	Johannes Notni (GER)
14:15	Initial Evaluation of <sup>68</sup> Ga-dota-en-pba as a PET Imaging Reporter (1.13)	Penelope Bouziotis (GRE)
<b>14:30 – 14:45</b>	<b>COFFEE AND TRADE EXHIBITS</b>	
<b>14:45 – 16:45</b>	<b>Scientific Session 4 – Theranostic Targeting Vectors (II)</b>	
<i>Chairpersons: Cathy Cutler (USA) and Sridhar Nimmagadda (USA)</i>		
14:45	Chemokine Receptor Type 4 (CXCR4) Targeted Agents for Imaging and Therapy (1.14)	Hans-J. Wester (GER)
15:15	A DOTA Based Bisphosphonate with an Albumin Binding Moiety for Delayed Body Clearance in Bone Targeting Radiotherapy (1.15)	Nina Pfannkuchen (GER)
15:30	Novel Radiopharmaceutical and Preclinical Aspects of <sup>68</sup> Ga-UBI: A Selective PET Tracer for Imaging of Infection (NR)	Thomas Ebenhan (ZAF)
15:45	Biology as a Model System (NR)	Sridhar Nimmagadda (USA)
16:15	A DOTA-Zoledronate Conjugate for PET-Diagnosis and Endoradiotherapy of Bone Metastases (NR)	Marian Meckel (GER)
16:30	Design and Synthesis of <sup>68</sup> Ga-based Ligand for ER+ Tumor Imaging (1.19)	Anupama Datta (IND)
<b>16:45 – 17:45</b>	<b>Poster Presentations</b>	

<b>18:30</b>	<i>Welcome Gala at the B &amp; O Railroad Museum</i>	
<b>FRIDAY, MARCH 13</b>		
07:00 – 17:00	Registration and Continental Breakfast - Johns Hopkins Thomas B. Turner Auditorium	
<b>08:00 – 08:30</b>	<b>PLENARY ADDRESS ~ Ralph Hruban (USA): Genetic Alterations in NETs (2.0)</b>	
<b>08:30 – 10:00</b>	<b>Scientific Session 5 – Established and Innovative Applications for Diagnosis</b>	
<i>Chairpersons: Mike Sathekge (ZAF) and Paula Jacobs (USA)</i>		
08:30	Bringing New Light to Old Tracers with <sup>68</sup> Ga: Galligas, MAA, and EDTA (2.20)	Michael Hofman (AUS)
09:00	Chemokine Receptor Type 4 (CXCR4) Targeting in Lympho-proliferative Diseases (2.21)	Ulrich Keller (GER)
09:30	Evaluation of DOTA-TOC PET/MRI Combined with Gadoxetate Enhanced MRI for the Evaluation of Neuroendocrine Tumors (2.22)	Thomas Hope (USA)
09:45	Can <sup>68</sup> Ga-DOTATATE Replace <sup>18</sup> F-FDG PET / CT for Detection of Bone Metastases in Small-Cell Lung Cancer? (2.23)	Wei Zhang (CHI)
<b>10:00 – 10:15</b>	<b>COFFEE AND TRADE EXHIBITS</b>	
<b>10:15 – 12:00</b>	<b>Scientific Session 6 – Targeting Prostate Cancer: Imaging and Therapy</b>	
<i>Chairpersons: Richard Wahl (USA) and Feng Wang (CHI)</i>		
10:15	NCI Resources for Translational Molecular Imaging (2.24)	Paula Jacobs (USA)
10:45	Targets for Prostate Cancer Imaging: Focus on PSMA (2.25)	Martin Pomper (USA)
11:15	Theranostics of Prostate Cancer and Lutetium-labeled PSMA (2.26)	Richard Baum (GER)
11:30	<sup>44</sup> Sc and <sup>177</sup> Lu-labeling of DOTA-PSMA DKFZ-617 for Dosimetry and Therapy of Prostate Cancer (2.27)	Elisabeth Eppard (GER)
11:45	A Preclinical Comparative Study of <sup>68</sup> Ga-Labeled DOTA, NOTA and HBED-CC Chelated PSMA-targeted Radiotracers (NR)	Sangeeta Ray (USA)
<b>12:00 – 13:00</b>	<b>LUNCH AND TRADE EXHIBITS</b>	
12:00 – 13:00	Satellite Meeting - Johns Hopkins Tilghman Auditorium	
<b>13:00 – 14:30</b>	<b>Scientific Session 7 – Targeting Prostate Cancer: Imaging and Therapy</b>	
<i>Chairpersons: Martin Pomper (USA) and John Babich (USA)</i>		
13:00	Radio-Nanomedicine as the Basis of Next Generation Theranostics (2.29)	Dong Soo Lee (KOR)
13:30	Role of <sup>68</sup> Ga PSMA PET/CT in Recurring and Metastatic Prostate Cancer #30	Harshad Kulkarni (GER)
14:00	Detection of Relapsing Prostate Cancer with PET/CT: Non-inferiority of <sup>68</sup> Ga Labeled PSMA-binding Peptide to <sup>11</sup> C-Choline in Extraprostatic	Sven Reske (GER)

	Relapse #31	
<b>14:30 – 14:45</b>	<b>COFFEE AND TRADE EXHIBITS</b>	
<b>Friday, March 13 - continued</b>		
<b>14:45 – 16:45</b>	<b>Scientific Session 8 – Peptide Receptor Radiotherapy: Status Quo and Where to Go</b>	
<i>Chairpersons: Ron Walker (USA) and Sue O’Dorisio (USA)</i>		
14:45	Dosimetry of Theranostic Agents (2.32)	Michael Lassmann (GER)
15:15	Targeting Growth Factor Receptors for Theranostics (2.33)	Jacek Capala (USA)
15:45	Progressive Free Survival and Overall Survival Time in Patients with GBM after <sup>213</sup> Bi-DOTA-substance P Therapy (2.34)	Leszek Krolicki (POL)
16:00	Review of Single and Multicenter Studies with Somatostatin-labeled Analogs (2.35)	Erik Mittra (USA)
16:30	Long Term Side Effects in Patients with Disseminated Neuroendocrine Tumors Who Underwent Tandem Peptide Receptor Radionuclide Therapy (PRRT) - <sup>90</sup> Y/ <sup>177</sup> Lu-DOTATATE (2.36)	Jolanta Kunikowska (POL)
<b>16:45 – 17:45</b>	<b>Poster Presentations</b>	
<b>18:00</b>	<b><i>Dinner on Own</i></b>	

<b>SATURDAY, MARCH 14</b>		
07:00 – 12:00	Registration and Continental Breakfast - Johns Hopkins Thomas B. Turner Auditorium	
<b>08:00 – 09:30</b>	<b>Scientific Session 9 – State-of-the-Art Management of NETs: Clinician and Patient Perspectives</b>	
<i>Chairpersons: Thomas O’Dorisio (USA) and Eric Liu (USA)</i>		
08:00	The Clinician’s Perspective (3.37)	Thomas O’Dorisio (USA)
08:30	The Patient’s Perspective (3.38)	Josh Mailman (USA)
09:00	Single-center Experience Over More Than a Decade Analyzing 1000 Neuroendocrine Neoplasm Patients Treated with Single- or Duo-Radionuclide Peptide Receptor Radionuclide Therapy (3.39)	Harshad Kulkarni (GER)
09:15	<sup>68</sup> Ga-DOTA-Octreotate PET/CT and Outcomes of Peptide Receptor Radionuclide Therapy for Paediatric Patients with Refractory Metastatic Neuroblastoma (3.40)	Michael Hofman (AUS)
<b>09:30 – 09:45</b>	<b>COFFEE AND TRADE EXHIBITS</b>	
<b>09:45 – 12:00</b>	<b>Scientific Session 10 – Gallium Approval in the US: Background and Moving Forward</b>	
<i>Chairpersons: Michael Graham (USA) and Baljinder Singh (IND)</i>		

09:45	The US Experience with Imaging and Therapy (3.41)	Ebrahim delPassand (USA)
10:15	The US Experience - Iowa (3.42)	Yusuf Menda (USA)
<b>Saturday, March 14 - continued</b>		
10:30	The US Experience - Vanderbilt (3.43)	Ron Walker (USA)
10:45	Pathway to Approval: FDA Perspective (3.44)	Dwaine Rieves (USA)
11:05	SNMMI Gallium Users Group: Moving Approval Forward in the US (3.45)	Michael Graham (USA)
11:25	Panel Discussion: Gallium Approval in the US (3.46)	Ebrahim delPassand (USA) Yusuf Menda (USA) Ron Walker (USA) Dwaine Rieves (USA) Michael Graham (USA) Richard Baum (GER)
<b>12:00 – 13:00</b>	<b>Lunch and Trade Exhibits</b>	
<b>13:00 – 15:00</b>	<b>Scientific Session 11 – How to Deliver Theranostics</b>	
<i>Chairpersons: Baljinder Singh (IND) and Erik Mittra (USA)</i>		
13:00	Updates from Clinical Trials on Radiopeptide Therapy (NR)	Lisa Bodei (ITA)
13:25	PRRT and Theranostics in Children (3.48)	Sue O’Dorisio (USA)
13:50	PRRT + Chemotherapy = Peptide Receptor Chemoradionuclide Therapy (PRCRT) (3.49)	Michael Hofman (AUS)
14:20 – 15:00	<b>CONGRESS HIGHLIGHTS AND LOOKING TO THE FUTURE: Richard Baum (3.52) and Frank Roesch (3.50)</b>	
<b>CLOSING COMMENTS AND AWARDS (3.53)</b> <b><u>ANNOUNCEMENT OF THE NEXT CONGRESS: RICHARD BAUM</u></b> <b>“4th Theranostics World Congress on <sup>68</sup>Ga and Peptide-related Radionuclide Therapy”</b> <b>Melbourne, Australi</b> <b>November 2016</b>		
<b>PATIENT PANEL WITH DRS. BAUM, LIU, O’DORISIO, WOLIN MODERATED BY JOSH MAILMAN (3.54)</b>  <b>END OF CONFERENCE</b>		